Drug updated on 10/28/2024
| Dosage Form | Injection (intravenous; atoltivimab/maftivimab/odesivimab: 241.7 mg/241.7 mg/241.7 mg per 14.5 mL [16.67 mg/16.67 mg/16.67 mg per mL] in a single dose vial; atoltivimab/maftivimab/odesivimab: 483.3 mg/483.3 mg/483.3 mg per 14.5 mL [33.33 mg/33.33 mg/33.33 mg per mL] in a single-dose vial) |
| Drug Class | Combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Inmazeb reduced the mortality rate by 17% in subjects with Ebola Virus Disease (EVD) when administered at a 3 ml/kg IV (intravenous) dose.
- ZMapp Plus showed superior effectiveness in treating EVD with a 91.2% effectiveness rate, while Ebanga demonstrated a higher mortality rate of 35.1% with a 50 mg/kg single IV dose, making Inmazeb more effective in reducing mortality compared to Ebanga.
- No specific population or subgroup data regarding the effectiveness of Inmazeb were provided in the studies.
- The most common adverse effects observed with Inmazeb include fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills.
- There is no specific safety comparison data provided between Inmazeb and other drugs such as ZMapp Plus and Ebanga in the reviewed studies, and no significant safety concerns were highlighted for specific population subgroups.
- The study indicates that Ebanga may be preferred in patients with cardiovascular complications, suggesting that this subgroup may experience a more favorable safety or effectiveness profile with Ebanga compared to other treatments. No other specific population types or subgroups are mentioned in the provided studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Inmazeb (atoltivimab, maftivimab, odesivimab-ebgn) Prescribing Information. | 2022 | Regeneron Pharmaceuticals Inc., Tarrytown, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020 | 2022 | Journal of Infection and Public Health |